Information for investors including share information, share analysis, shareholder news and annual reports.

Q2 2014 results: 23 Jul 2014

View Q2 results details and CEO & CFO videos

stock prices
Investing in GSK

Reasons to invest in GSK - a global healthcare company enabling people to do more, feel better and live longer.

Corporate reporting

Find out how GSK is performing with our Annual Report, Corporate Responsibility Report and financial summary.

Press releases

These press releases are intended for business journalists and analysts/investors.
24 July 2014

FDA approves Flonase allergy relief for sale over-the-counter in the United States

No. 1 prescribed allergy treatment ingredient1 to be available OTC

24 July 2014

GSK announces EU regulatory submission for malaria vaccine candidate RTS,S

GSK announced today that it has submitted a regulatory application to the European Medicines Agency (EMA) for its malaria vaccine candidate, RTS,S.

23 July 2014

Results announcement for the second quarter 2014

GSK delivers Q2 2014 turnover £5.6 billion (-4%) and core EPS 19.1p (-12%) on ex-divestment basis (both CER). Q2 dividend 19p (+6%).

UK Map
Investor relations UK
GlaxoSmithKline plc
   Tel: 020 8047 5000
980 Great West Road
    Fax: 020 8047 7807
Middlesex TW8 9GS

Investor downloads

Our product pipeline      
Our product pipeline 0.3MB